Top Page
Genetic Technologies
(OTC:GTG)
Genetic Technologies (GTG) vs. iShares MSCI Australia ETF (EWA)
Genetic Technologies Business Overview & Revenue Model
Genetic Technologies Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 7.66M | 10.35M | 6.79M | 120.55K | 837.87K | Gross Profit |
| 3.90M | 6.01M | 6.47M | -240.47K | 736.43K | EBIT |
| -12.21M | -10.42M | -7.54M | -7.42M | -5.94M | EBITDA |
| -11.43M | -11.20M | -7.20M | -7.06M | -5.87M | Net Income Common Stockholders |
| -12.02M | -11.75M | -7.13M | -7.08M | -6.29M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.02M | 7.87M | 11.73M | 20.90M | 14.22M | Total Assets |
| 6.19M | 14.86M | 20.80M | 22.97M | 15.63M | Total Debt |
| 875.19K | 532.85K | 652.53K | 204.04K | 481.79K | Net Debt |
| -145.42K | -7.32M | -11.08M | -20.70M | -13.73M | Total Liabilities |
| 4.36M | 3.69M | 4.37M | 1.44M | 1.64M | Stockholders Equity |
| 1.83M | 11.16M | 16.43M | 21.53M | 13.99M |
| Cash Flow | Free Cash Flow | |||
| -9.71M | -9.74M | -5.76M | -6.94M | -5.75M | Operating Cash Flow |
| -9.68M | -9.72M | -5.66M | -6.30M | -5.71M | Investing Cash Flow |
| 114.90K | -311.94K | -3.49M | -642.00K | 64.79K | Financing Cash Flow |
| 2.82M | 5.92M | -279.06K | 13.94M | 18.36M |
Genetic Technologies Technical Analysis
Genetic Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% | |
49 Neutral | AU$46.33M | ― | -39.07% | ― | 26.07% | 0.85% | |
47 Neutral | AU$22.46M | ― | -51.49% | ― | 80.84% | 57.59% | |
45 Neutral | AU$18.00M | ― | -71.10% | ― | ― | 76.17% | |
43 Neutral | AU$5.67M | ― | -181.97% | ― | -11.76% | 22.83% | |
40 Underperform | AU$25.25M | ― | -104.23% | ― | ― | -17.26% | |
39 Underperform | AU$2.42M | ― | ― | 55.07% | 88.20% |
Genetic Technologies Corporate Events
Genetic Technologies Limited has announced the acquisition of Ellerfield Wealth Pty Ltd and Walker Capital Private Wealth Pty Ltd, marking a significant step in its transition to a diversified financial services group. These acquisitions are expected to enhance the company’s positioning in the wealth management sector by leveraging a combined client base and operational infrastructure, aligning with its long-term strategy for growth through organic and acquisition opportunities. The transactions are subject to regulatory and shareholder approvals, and the company plans to conduct an equity raise to comply with ASX listing requirements.
Genetic Technologies Limited has announced the application for quotation of over 1.16 billion fully paid ordinary securities on the Australian Securities Exchange. This move is part of previously announced transactions and could potentially enhance the company’s liquidity and market presence, impacting its operational capabilities and stakeholder interests.
Genetic Technologies Limited has announced the quotation of 26,493,450 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the company’s financial flexibility and operational capacity.
Genetic Technologies Limited has announced a change in its registered office and principal place of business, effective May 14, 2025. The new registered office is located at Level 5, 126-130 Phillip Street, Sydney, while the principal place of business has moved to the Kon-Tiki Business Centre in Maroochydore. This relocation may impact the company’s operations and stakeholder interactions by potentially enhancing its strategic positioning within the industry.
Genetic Technologies Limited announced the cessation of John Polinelli as a director, effective May 14, 2025. This update, provided under the ASX listing rule 3.19A.3, indicates no relevant interests in securities held by the departing director, suggesting minimal immediate impact on the company’s operations or market positioning.
Genetic Technologies Limited has announced significant changes in its board and executive management. Michael Walker has been appointed as the Executive Chairman and Managing Director, while William Musgrave joins as a non-executive director, bringing extensive commercial and legal experience. Additionally, Jules Grove has been appointed as the Chief Financial Officer, and Priyamvada Rasal as the Joint Company Secretary. These appointments are expected to strengthen the company’s leadership and support its strategic growth initiatives.
Genetic Technologies Limited has successfully completed its Deed of Company Arrangement (DOCA), marking its exit from external administration. The company’s existing directors have resigned, and new directors have taken control. Additionally, a Creditors’ Trust has been established, with creditors now becoming beneficiaries of this trust rather than creditors of the company. There is no expected return to unsecured creditors, but any potential returns will be communicated by the trustees.
Genetic Technologies Limited has announced the appointment of Anthony Hartman as a director, effective May 14, 2025. The notice indicates that Hartman currently holds no relevant interests in securities, either as a registered holder or otherwise, and has no interests in any contracts related to the company. This appointment is a procedural update required under ASX listing rules and does not directly impact the company’s operations or market positioning.
Genetic Technologies Limited has announced a proposed issue of 26,493,450 ordinary fully paid securities, set to be issued on May 21, 2025. This move is part of a placement or other type of issue, which could potentially impact the company’s market positioning by increasing its capital base, thereby enabling further growth and development in its genetic testing services.
Genetic Technologies Limited announced a proposed issue of up to 1,163,511,764 ordinary fully paid securities, with the issue date set for May 21, 2025. This strategic move is aimed at enhancing the company’s financial position and potentially expanding its market reach, which may have significant implications for its operations and industry standing.
Genetic Technologies Limited announced significant changes in its board of directors following a General Meeting of shareholders. Three directors, George Muchnicki, Peter Rubinstein, and Lindsay Wakefield, have resigned, and Michael Walker, Anthony Hartman, and John Polinelli have been appointed as non-executive directors. These changes are expected to bring new perspectives and expertise to the company’s strategic direction.
Genetic Technologies Limited announced the successful outcomes of its General Meeting of shareholders, where all proposed resolutions were approved by poll. The resolutions included the allotment and issue of shares to Walker Investments and Benelong Capital Partners, as well as the appointment of three new directors, Michael Walker, John Polinelli, and Anthony Hartman. This development is likely to strengthen the company’s governance and strategic direction, potentially impacting its market positioning positively.
Genetic Technologies Limited, currently under a Deed of Company Arrangement, has announced a General Meeting of Shareholders scheduled for May 14, 2025. This meeting will be held in Sydney, Australia, and shareholders are encouraged to attend. The company has opted to provide meeting materials electronically, accessible via their website or the ASX market announcements page, reflecting a shift towards digital communication with stakeholders.
Genetic Technologies Limited, currently under voluntary administration, has executed a Deed of Company Arrangement (DOCA) with Benelong Capital Partners Pty Ltd. This development follows a resolution by creditors and involves the company’s recapitalization, subject to shareholder approval. The Deed Administrators, appointed by FTI Consulting, will oversee the process until all conditions are met, impacting shareholder interests as detailed notices will be issued soon.